SCNX Shares Plunge 26.5% Amid $3.9M Raise and Arbli™ Commercial Launch
By ATTN Desk · Editorial oversight: Sean Han
Introduction
SCIENTURE HOLDINGS INC (NASDAQ: SCNX) is a holding company for pharmaceutical operating entities focused on developing, commercializing, and distributing specialty products. As of October 24, 2025, SCNX shares closed at $1.91, down 26.54% on the NASDAQ, with a trading volume of 9,475,282. The 52-week range stands at $0.461–$9.550.
Corporate Structure and Workforce
Through its wholly owned subsidiary, Scienture LLC, the company operates from Hauppauge, New York. Founded in 2019, Scienture LLC comprises a team of industry professionals engaged in developing drug-device combinations and biosimilar products. According to its LinkedIn profile, the subsidiary employs between 2 and 10 staff members.
Pharmaceuticals by freestocks
Recent Developments
On August 14, 2025, Scienture Holdings announced a registered direct offering of 3,225,000 common shares at $1.20 per share, expected to generate gross proceeds of $3.9 million. The transaction, led by Maxim Group LLC, is set to close on August 15, 2025, subject to customary closing conditions.
In market-access initiatives, Scienture secured multiple commercial Group Purchasing Organization (GPO) agreements, extending coverage of Arbli™ (losartan potassium oral suspension) to over 2,500 U.S. healthcare institutions. A separate PBM-led GPO rebate agreement aims for formulary inclusion within the $256 million U.S. losartan market. The company has also shipped initial launch quantities of Arbli™ to its 3PL distribution center and received its first wholesaler order.
Financial and Strategic Analysis
As of October 24, 2025, key metrics from Yahoo Finance include:
| Metric | Value |
|---|---|
| Market Capitalization | $64.11 million |
| Enterprise Value | $20.87 million |
| Trailing P/E (TTM) | 1.70 |
| Price/Sales (TTM) | 59.78 |
| Price/Book (MRQ) | 0.22 |
| Revenue (TTM) | $128,200 |
| Net Income (TTM) | –$19.77 million |
| Total Cash (MRQ) | $15,390 |
| Total Debt/Equity (MRQ) | 5.30% |
The company's revenue base is limited, but it has made progress in advancing Arbli™ toward commercialization. The direct offering aims to enhance liquidity, although the share price is below recent trading levels. Notably, the company exhibits a low price/book ratio and a relatively high enterprise value/revenue multiple.
Market Position and Industry Context
Scienture operates within specialty pharmaceutical segments that address unmet patient needs, including:
- CNS/pain management: SCN-104 drug-device combination
- Cardiovascular biosimilars: SCN-106
- Post-operative care injections: SCN-107
The FDA approval of its new drug application (NDA) for SCN-102 (Arbli™) positions the company in a market that generated approximately $1.5 billion in global losartan sales in 2024. The commercial GPO agreements and PBM rebate structures are intended to facilitate institutional adoption. With limited direct competition in oral suspension formulations, Scienture’s strategy includes utilizing specialty pharmacy channels and hospital networks.
tl;dr
On October 24, 2025, SCNX shares fell 26.54% to $1.91 amid heightened trading. In mid-August 2025, Scienture closed a $3.9 million registered direct offering at $1.20 per share. The company has initiated U.S. commercialization of Arbli™ (losartan potassium oral suspension), securing GPO agreements covering over 2,500 institutions and completing initial 3PL shipments. These developments may influence its revenue outlook in the $256 million U.S. losartan market.